Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-23-006677
Filing Date
2023-01-26
Accepted
2023-01-26 06:03:37
Documents
1
Period of Report
2023-01-25

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm234482-1_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm234482-1_4seq1.xml 4 3644
  Complete submission text file 0001104659-23-006677.txt   5588
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Issuer) CIK: 0000894158 (see all company filings)

EIN.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ELYS GAME TECHNOLOGY CORP. 130 ADELAIDE STREET WEST, SUITE 701 TORONTO A6 M5H2K4
Business Address C/O ELYS GAME TECHNOLOGY CORP. 130 ADELAIDE STREET WEST, SUITE 701 TORONTO A6 M5H2K4 301 944 6600
SHALLCROSS STEVEN A (Reporting) CIK: 0001263501 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-12584 | Film No.: 23553824